Introduction
============

Ovarian cancer incidence is estimated at 238,000 patients worldwide per year, making it the seventh most common type of cancer among women.[@b1-dddt-11-3471] In the USA, epithelial ovarian cancer is the fifth most common cause of cancer mortality among women, and in 2017, it is estimated that 22,440 new diagnoses and 14,080 deaths from this neoplasm will occur.[@b2-dddt-11-3471] A number of characteristics, such as family history of ovarian cancer, reproductive history, and *BRCA* mutation profile, have been shown to play a role in a woman's risk of developing ovarian cancer.[@b3-dddt-11-3471]--[@b5-dddt-11-3471] Thirty-nine percent of women with a *BRCA1* mutation and 11%--17% of women with a *BRCA2* mutation will develop ovarian cancer by 70 years of age.[@b3-dddt-11-3471],[@b4-dddt-11-3471] Prognosis for ovarian cancer patients is poor, predominantly because it is diagnosed at a late stage when the disease is already widely metastatic, with 75% of women with ovarian cancer being diagnosed at Stage IIIC or IV.[@b6-dddt-11-3471],[@b7-dddt-11-3471]

The standard of care consists of cytoreductive surgery and postoperative or adjuvant chemotherapy.[@b8-dddt-11-3471] Platinum-based chemotherapy has been the backbone of ovarian cancer treatment and is used until the tumor becomes resistant.[@b8-dddt-11-3471] Advanced ovarian cancer patients receive multiple lines of therapy, with ever-decreasing period of treatment-free times.[@b8-dddt-11-3471] Attempts to improve patients' survival include the use of neoadjuvant chemotherapy when complete debulking is not feasible,[@b9-dddt-11-3471]--[@b11-dddt-11-3471] intraperitoneal treatment,[@b12-dddt-11-3471],[@b13-dddt-11-3471] and use of maintenance therapy.[@b14-dddt-11-3471]

The most recent changes in ovarian cancer treatment are the approval of targeted therapies such as bevacizumab and olaparib.[@b15-dddt-11-3471],[@b16-dddt-11-3471] Bevacizumab, first approved by the European Medicines Agency in 2011, is a monoclonal antibody that binds to all isoforms of the vascular endothelial growth factor receptor ligand.[@b17-dddt-11-3471] A number of studies showed that use of bevacizumab, either alone or in combination with chemotherapy, could be beneficial in various treatment settings such as front line, recurrent patients, platinum-sensitive, and platinum-resistant patients.[@b18-dddt-11-3471]--[@b22-dddt-11-3471] The US Food and Drug Administration (FDA) initially approved bevacizumab in combination with chemotherapy for the treatment of platinum-resistant ovarian cancer patients in November 2014.[@b15-dddt-11-3471]

Olaparib is a poly (ADP-ribose) polymerase inhibitor that induces synthetic lethality in *BRCA1/2*-deficient tumor cells.[@b23-dddt-11-3471] In December 2014, the FDA approved olaparib for patients with advanced ovarian cancer who received treatment with three or more lines of chemotherapy and who have a germline *BRCA* mutation, while the European Medicines Agency approved it as monotherapy for the maintenance of platinum-sensitive relapsed *BRCA*-mutated patients whose previous treatment with platinum-based chemotherapy led to a sustained response.[@b16-dddt-11-3471],[@b24-dddt-11-3471]

In this context, a multi-country survey was designed to investigate current treatment of advanced ovarian cancer patients. More specifically, this survey investigated the proportion of patients in treatment versus those in maintenance, and the type of treatment received depending on their *BRCA* mutation status. To our knowledge, this was the first research investigating real-world pharmacologic therapy prescribed to ovarian cancer patients in multiple countries.

Patients and methods
====================

Study sample design
-------------------

Medical and gynecologic oncologists from France, Germany, Italy, the UK, and the USA were invited to participate in an online survey aimed at better understanding the medical management and treatment regimens of advanced stage epithelial ovarian cancer, in both *BRCA*-positive and -negative patients.

In the USA, a universal sample frame of ovarian cancer-treating oncologists was created by sourcing Symphony Health Analytics' 2016 insurance claims activity for medical and gynecologic oncologists in the USA for the C56 series of International Classification of Diseases-10 codes used in diagnosing and treating ovarian cancer. Overall, 4,219 oncologists with activity related to the care of ovarian cancer patients were identified. This list of oncologists served as the sample frame for this survey and they were invited to the survey. An external provider, M3 Global Research, was used in Europe to contact medical and gynecologic oncologists. M3 Global Research is a panel provider which has access to a broad range of physicians, including those who specialize in gynecologic cancer treatment. A total of 369 medical and gynecologic oncologists were contacted in France, 551 in Germany, 340 in Italy, and 669 in the UK. Oncologists were eligible to participate if they personally managed at least 15 ovarian cancer patients at the time of survey participation. Altogether, 361 European oncologists responded to the survey and 138 met the eligibility criteria and completed the survey. In the USA, a total of 188 oncologists responded to the survey, with 132 meeting the eligibility criteria. Response rate could not be calculated since the proportion of emailed physicians who fit in the inclusion criteria or who have an active email address is unknown.

Participants were offered an industry-standard honorarium as compensation for their time in completing the survey. The survey was administered online and was fielded from December 16, 2016 to January 23, 2017.

Survey design
-------------

A questionnaire was developed to collect anonymized information on patients with advanced ovarian cancer. We developed and pretested this instrument through interviews and consultations with three ovarian cancer-treating oncologists before launching the survey online. The wording of the questions and their order were carefully decided to minimize any influence that one question may have on subsequent questions. The online questionnaire consisted largely of quantitative questions, and covered the following topics: patients' disease stages; proportion of *BRCA*-tested patients; outcome of *BRCA* tests and reasons for not testing; proportion of patients per line of therapy; management of advanced ovarian cancer patients per line of therapy depending on their *BRCA* status; and whether they were on chemotherapy or maintenance therapy (questionnaire available upon request).

Data analysis
-------------

All survey data were analyzed in aggregate, and the study authors were blinded to the individual identities of the survey respondents. The planned analyses for quantitative data were descriptive and included means and percentages. Data from each respondent were weighted by the total number of advanced ovarian cancer patients they see to account for the differences between large and small practices. No formal statistical tests were performed. Qualitative data were analyzed thematically and coded according to the main themes of the survey questions. Any response that addressed multiple themes was counted as multiple comments.

Ethics
------

By electing to complete the survey, respondents provided consent to use their anonymous responses to the survey questions. The study did not involve patients, and data on patient characteristics were provided only in aggregate. As such, there was no institutional review board and/or licensing committee involved in approving the research and no need for informed consent from the participants as per the US regulations edited by the US Department of Health and Human Services, Protection of Human Subjects 45 CFR §46.101, paragraph (b) (4).[@b25-dddt-11-3471]

Results
=======

A total of 549 physicians responded to the survey invitation and 270 met the eligibility criteria and completed the survey (49% completion rate). The number of respondents by country who completed the survey included 138 oncologists in Europe (37 in France, 37 in Germany, 31 in Italy, and 33 in the UK), and 132 in the USA.

Characteristics of treated ovarian cancer patient population
------------------------------------------------------------

The mean number of treated ovarian cancer patients per respondent was 36.7 in Italy, 46 in Germany, 51.2 in the USA, 64 in France, and 86.8 in the UK. Stages III and IV represented the vast majority of patients, ranging from 65% in Italy to 81% in the USA. Germany, Italy, and the USA had the lowest proportion of ovarian cancer patients in neoadjuvant treatment (16%, 15%, and 16%, respectively) versus 22% in the UK and 26% in France. Germany had the highest proportion of patients in first-line treatment at 44%, compared with 30%--36% in all other countries ([Table 1](#t1-dddt-11-3471){ref-type="table"}). In terms of the type of treatment, 60% of advanced ovarian cancer patients were on active treatment chemotherapy, 20% were on maintenance therapy, and 20% were not currently treated. This split was observed for all lines of treatment, and there were no meaningful country-level differences ([Figure S1](#SD1-dddt-11-3471){ref-type="supplementary-material"}). Resistance or absence of response to platinum-based therapy increased with the line of treatment, ranging from 19% in Germany and the USA to 33% in Italy in first line. In the fourth line or above, resistance or absence of response to platinum-based chemotherapy ranged from 49% to 65% ([Figure S2](#SD2-dddt-11-3471){ref-type="supplementary-material"}).

*BRCA* mutation status
----------------------

The proportion of patients tested for *BRCA* mutations was 45% in Italy, 50% in the UK, 61% in France, 65% in Germany, and 73% in the USA. The main reasons for not testing patients for *BRCA* mutations were country specific: absence of family history or risk factor was the main reason in Italy (28%), Germany (34%), and the UK (43%). In Italy, both the absence of family history or risk factor and the patient's condition preventing a biopsy were mentioned (28% each). In France, the patient's condition preventing a biopsy was the main barrier (35%), while in the USA, it was mainly the patient's choice not to be tested (49%).

Of the patients who were tested for *BRCA* mutations, 10% had a positive test in the UK, 13% in France and Germany, 16% in the USA, and 21% in Italy.

Pharmaceutical management of *BRCA*-negative patients
-----------------------------------------------------

[Figure 1](#f1-dddt-11-3471){ref-type="fig"} shows how *BRCA*-negative patients were treated in each country. While platinum-based chemotherapy was prescribed the most in first line in the USA, UK, Italy, and France (ranging from 55% to 93% of patients), German doctors preferred a combination of bevacizumab and chemotherapy (53% of patients). Shares of platinum-based chemotherapy decreased as patients progressed through treatment line, to the benefit of non-platinum-based chemotherapies. There was no consensus regarding the use of bevacizumab; its shares varied per country and per line of treatment.

For maintenance of *BRCA*-negative patients, prescriptions were largely dominated by bevacizumab in monotherapy in first and second line. The proportion of patients receiving non-platinum-based chemotherapy increased in the third and fourth line ([Figure 2](#f2-dddt-11-3471){ref-type="fig"}).

Of note, some use of olaparib was observed in both the treatment and maintenance setting of *BRCA*-negative patients, when olaparib was indicated in *BRCA*-positive patients only at the time of the survey ([Figures 1](#f1-dddt-11-3471){ref-type="fig"} and [2](#f2-dddt-11-3471){ref-type="fig"}).

Pharmaceutical management of *BRCA*-positive patients
-----------------------------------------------------

Similar to *BRCA*-negative patients, *BRCA*-positive patients were largely treated with platinum-based chemotherapy in first line in the USA, UK, Italy, and France, while German doctors predominantly prescribed bevacizumab in combination with chemotherapy ([Figure 3](#f3-dddt-11-3471){ref-type="fig"}). Use of platinum-based chemotherapy decreased as patients recurred, with a switch toward non-platinum-based chemotherapy. Prescription of olaparib varied per country and per line of treatment: 3% of patients received it in first line in the USA compared with 22% in France. Although olaparib was only approved in the maintenance setting in Europe, all four European countries included in our survey reported using olaparib in the treatment setting.

Regarding maintenance of *BRCA*-positive patients, prescriptions of olaparib and bevacizumab represented a large proportion of patients in France, Germany, and Italy for all treatment lines ([Figure 4](#f4-dddt-11-3471){ref-type="fig"}). In the UK, chemotherapy (either platinum based or non-platinum based) represented the majority of treatments in first and second line, with a switch to olaparib and bevacizumab in third and fourth line. In the USA, olaparib was used for the maintenance of *BRCA*-positive patients in all lines of treatment, despite its approval in the treatment setting only.

Discussion
==========

The management of advanced ovarian cancer has rapidly changed in the past 2 years with the approval of targeted therapies such as bevacizumab and olaparib.[@b15-dddt-11-3471],[@b16-dddt-11-3471] We designed a survey to investigate the real-world current treatment practices in the therapy and the maintenance setting, and depending on patients' *BRCA* status, in the USA and four European countries.

Our survey identified a consensus across countries regarding the proportion of advanced ovarian cancer patients receiving treatment versus those in maintenance therapy. More specifically, shares of patients in treatment, maintenance therapy, and remission were the same across lines of treatment. In all five surveyed countries, and for all lines of treatment, 60% of patients were in treatment, 20% in maintenance, and 20% in remission. Similarly, the emergence of platinum resistance was the same across countries.

We observed a number of country-specific differences for other aspects investigated in our survey. The proportion of *BRCA*-tested patients was highest in the USA at 73% and lowest in Italy and the UK at 45% and 50%, respectively. Similarly, slight variations in the proportion of patients receiving neoadjuvant therapy were noted, with the highest proportion in France at 26% and the lowest in Germany at 16%. No specific reasons were identified for these regional differences.

Our survey highlights the magnitude of olaparib and bevacizumab prescription outside of their approved indication. Although olaparib was only indicated for *BRCA*-positive patients at the time of our survey, some prescribing to *BRCA*-negative patients in maintenance was reported, especially in Europe, and to a lesser extent in the treatment setting. The rationale for using olaparib in *BRCA*-negative patients was not investigated, and it is not known what proportion of patients had a positive outcome. Looking at *BRCA*-positive patients in the USA, where olaparib is indicated for the treatment of *BRCA*-positive patients who received three or more lines of treatment, our data identified some prescribing as early as first line, and in both the treatment and the maintenance setting. Similarly, in Europe, where olaparib was indicated in the maintenance setting only, some *BRCA*-positive patients received olaparib as treatment.

As for bevacizumab, its indication coverage was broad in Europe, where it can be used in front line, in the maintenance setting, and for both recurrent platinum-sensitive and platinum-resistant patients. As expected, we reported a broad range of bevacizumab prescribing, with roughly one-quarter of patients receiving it either in monotherapy or in combination with chemotherapy in the treatment setting, and one third in the maintenance setting. In the USA, where bevacizumab was indicated in the treatment of recurrent platinum-resistant patients in combination with chemotherapy at the time of our survey, our data confirmed that it was largely used as per its indication in the treatment setting, although we observed some off-label use in front line. However, bevacizumab was also largely used in monotherapy in the maintenance setting, which was outside of its indication in the USA.

We hypothesize that prescribing of bevacizumab and olaparib outside of their indications is driven by either off-label use or inclusion in clinical trials. This is in line with the National Comprehensive Cancer Network guidelines that recommend enrolling advanced ovarian cancer patients who relapse on clinical trials as soon as possible.[@b26-dddt-11-3471]

The poor prognosis in advanced ovarian cancer emphasizes the need for more options to be developed. The treatment algorithm for ovarian cancer is expected to continue to change with the approval of rucaparib by the FDA in December 2016 for the treatment of *BRCA*-positive ovarian cancer patients who have been treated with two or more chemotherapies, and the investigation of other targeted therapies such as niraparib. However, the true impact of these drugs on patient outcomes remains to be seen.

This survey has a number of limitations. Although this survey was distributed to a wide array of oncologists, this may not be a representative sample of ovarian cancer treating physicians as information about nonresponders was not collected. Therefore, caution should be used when generalizing results of this subset of oncologists to the entire advanced ovarian cancer treating physician population. As with any web-based survey, this study is susceptible to both selection bias and reporting bias. Importantly, all respondents answered the same survey questions. There were no differences in the questionnaires, outside of translation, regardless of whether respondents were recruited by the Deerfield Institute or the M3 panel.

Conclusion
==========

Our survey illustrates the complexity of advanced ovarian cancer management and highlights country differences when it comes to the management of these patients. First, *BRCA* testing was not performed systematically, which raises concerns regarding the access to the most appropriate treatment for the patients whose *BRCA* status is unknown, especially in Italy and the UK. Second, although off-label prescription of targeted therapy was observed in all surveyed countries, there was no consensus regarding when these therapies could be used off label. Similarly, the preference for chemotherapeutic regimens or targeted therapy as per the disease stage varied in each country. These findings suggest the optimum usage of targeted therapies still needs to be determined.

Supplementary materials
=======================

###### 

Proportion of patients as per the type of management in each country.

**Notes:** (**A**) First-line treatment, (**B**) second-line treatment, (**C**) third-line treatment, (**D**) fourth line or above. Based on 37 oncologists in France, 37 in Germany, 31 in Italy, 33 in the UK, and 132 in the USA.

###### 

Percentage of patients who are refractory or resistant to platinum-based chemotherapy, as per the country and the line of therapy.

**Notes:** Based on 37 oncologists in France, 37 in Germany, 31 in Italy, 33 in the UK, and 132 in the USA.
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![Treatment of *BRCA*-negative ovarian cancer patients.\
**Notes:** Proportion of patients split by country and type of therapy: (**A**) first-line treatment, (**B**) second-line treatment, (**C**) third-line treatment, (**D**) fourth-line treatment or more.](dddt-11-3471Fig1){#f1-dddt-11-3471}

![Maintenance of *BRCA*-negative ovarian cancer patients.\
**Notes:** Proportion of patients split by country and type of therapy: (**A**) first-line treatment, (**B**) second-line treatment, (**C**) third-line treatment, (**D**) fourth-line treatment or more.](dddt-11-3471Fig2){#f2-dddt-11-3471}

![Treatment of *BRCA*-positive ovarian cancer patients.\
**Notes:** Proportion of patients split by country and type of therapy: (**A**) first-line treatment, (**B**) second-line treatment, (**C**) third-line treatment, (**D**) fourth-line treatment or more.](dddt-11-3471Fig3){#f3-dddt-11-3471}

![Maintenance of *BRCA*-positive ovarian cancer patients.\
**Notes:** Proportion of patients split by country and type of therapy. (**A**) first-line treatment, (**B**) second-line treatment, (**C**) third-line treatment, (**D**) fourth-line treatment or more.](dddt-11-3471Fig4){#f4-dddt-11-3471}

###### 

Proportion of patients per line of treatment per country

  Country   Number of ovarian cancer patients (mean)   Stage I, %   Stage II, %   Stage III, %   Stage IV, %
  --------- ------------------------------------------ ------------ ------------- -------------- -------------
  France    64                                         10           14            32             45
  Germany   46                                         9            14            40             37
  Italy     37                                         16           19            33             32
  UK        878                                        10           14            36             40
  USA       51                                         9            9             52             29

**Notes:** Based on 37 oncologists in France, 37 in Germany, 31 in Italy, 33 in the UK, and 132 in the USA.
